Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Poseida Therapeutics Inc (PSTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Poseida's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.790 +0.020    +0.72%
02/05 - Closed. Currency in USD ( Disclaimer )
Pre Market
2.840
+0.050
+1.792%
13:44:54 - Real-time Data
  • Volume: 1,355,800
  • Bid/Ask: 2.810 / 2.990
  • Day's Range: 2.740 - 2.970
Type:  Equity
Market:  United States
Poseida 2.790 +0.020 +0.72%

Poseida Company Profile

 
Read the Poseida Therapeutics Inc company profile to learn more about the business and the management team. View Poseida Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

330

Equity Type

ORD

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Contact Information

Address 9390 Towne Centre Drive Suite 200
San Diego, 92121
United States
Phone 858 779 3100
Fax -

Top Executives

Name Age Since Title
Mark J. Gergen 61 2018 Executive Chairman of the Board
Cynthia L. Collins 66 2021 Independent Director
John P. Schmid 61 2018 Lead Independent Director
Luca Gattinoni - 2021 Member of Scientific Advisory Board
Luke David Corning 42 2020 Independent Director
Mark A. Kay 65 2023 Member of Gene Therapy Scientific Advisory Board
Marcea Bland Lloyd 75 2019 Independent Director
Carl H. June 69 2021 Chairman of Cell Therapy Scientific Advisory Board
Jan Joseph Melenhorst - 2021 Member of Scientific Advisory Board
Christine Brown - 2021 Member of Scientific Advisory Board
Julian Grunewald - 2023 Member of Gene Therapy Scientific Advisory Board
Kathryn A. Whitehead - 2023 Member of Gene Therapy Scientific Advisory Board
Ian E. Alexander - 2023 Member of Gene Therapy Scientific Advisory Board
Charles M. Baum 66 2022 Independent Director
Rafael G. Amado 60 2023 Director
George McDonald Church 70 2022 Chairman of Gene Therapy Scientific Advisory Board
Mark Tracy - 2023 Member of Gene Therapy Scientific Advisory Board
Kristin Yarema 53 2023 President, CEO & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PSTX Price Commentary

Write your thoughts about Poseida Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email